Allogeneic NK Cells therapy (Incyte Corp)

N/A

Report date: 2025/11/07 20:01:05

Base Information

Drug NameAllogeneic NK Cells therapy (Incyte Corp)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesIncyte Corp

China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp

Inactive CompaniesN/A

Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8]

Inactive IndicationsN/A

Other Information

ATC CodeN/A